Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for folic acid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Folicacid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials Folicacid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials Folicacid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials de Bree A, van Mierlo LA, Draijer R CRD summary The review aimed to quantify the effect of folicacid on endothelial function and concluded that high doses improved function after four weeks (...) of supplementation. The presence of review methodology and reporting issues, coupled with the small sample sizes of included studies, means the authors' conclusions should be interpreted with caution. Authors' objectives To quantify the effect of folicacid on endothelial function, as measured with the use of flow-mediated dilatation. Searching MEDLINE was searched from 1966 to September 2005 for studies published in English; search terms were reported. Conference abstract books and reference lists of obtained
Efficacy of folicacid supplementation in stroke prevention: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Folicacid and risk of twinning: a systematic review of the recent literature, July 1994 to July 2006 Folicacid and risk of twinning: a systematic review of the recent literature, July 1994 to July 2006 Folicacid and risk of twinning: a systematic review of the recent literature, July 1994 to July 2006 Muggli E E, Halliday J L CRD summary The authors concluded that there is evidence of a possible association between periconceptional folicacid and the risk of twinning, but further research (...) is required. The authors' cautious conclusions appear to reflect the limited data, but the poorly defined review question, inadequate reporting of the review methods and inadequate quality assessment make it difficult to assess the reliability of these conclusions. Authors' objectives To examine the association between periconceptional folicacid (FA) supplementation and fortification of foods with FA and the risk of twinning. Searching The Cochrane Library (Issue 4, 2005), MEDLINE via PubMed, MEDLINE
Cost-effectiveness of a folicacid fortification program in Chile Cost-effectiveness of a folicacid fortification program in Chile Cost-effectiveness of a folicacid fortification program in Chile Llanos A, Hertrampf E, Cortes F, Pardo A, Grosse S D, Uauy R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. CRD summary This study determined the cost-effectiveness of wheat flour fortified with folicacid, compared with standard wheat flour, in the periconceptional period to reduce neural tube defects (NTDs) in all births weighing more than 499 g in Chile. The authors concluded that the programme was a cost-effective intervention for the prevention of NTDs in Chile. The quality of the study methodology was satisfactory, with good reporting
Folicacid: a public-health challenge. Despite worldwide public-health campaigns recommending periconceptional daily supplementation of synthetic folicacid to reduce the risk of neural tube defects, many women are not following these recommendations. At the same time, in most European countries no decline in defects has been recorded in recent years. Vulnerable groups are those with a low standard of education, young people, and women with unplanned pregnancies. Furthermore, in most countries (...) without mandatory fortification, the general population is not consuming the recommended 0.4 mg of food folate per day. Voluntary fortification improves the situation, but does not reach all parts of the population. In the USA, Canada, and Chile, mandatory fortification of flour substantially improved folate and homocysteine status, and neural tube defects rates fell by between 31% and 78%. Nevertheless, many countries do not choose mandatory folicacid fortification, in part because expected
Effects of routine prophylactic supplementation with iron and folicacid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Anaemia caused by iron deficiency is common in children younger than age 5 years in eastern Africa. However, there is concern that universal supplementation of children with iron and folicacid in areas of high malaria transmission might be harmful.We did a randomised (...) , placebo-controlled trial, of children aged 1-35 months and living in Pemba, Zanzibar. We assigned children to daily oral supplementation with: iron (12.5 mg) and folicacid (50 mug; n=7950), iron, folicacid, and zinc (n=8120), or placebo (n=8006); children aged 1-11 months received half the dose. Our primary endpoints were all-cause mortality and admission to hospital. Analyses were by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number
2006LancetControlled trial quality: predicted high
Effect of routine prophylactic supplementation with iron and folicacid on preschool child mortality in southern Nepal: community-based, cluster-randomised, placebo-controlled trial. Iron deficiency is widespread in the developing world and is especially common in young children who live on the Indian subcontinent. Supplementation with iron and folicacid alleviates severe anaemia and enhances neurodevelopment in deficient populations, but little is known about the risks of mortality (...) and morbidity associated with supplementation.We did a community-based, cluster-randomised, double-masked, placebo-controlled, 2x2 factorial trial in children aged 1-36 months and residing in southern Nepal. We randomly assigned children daily oral supplementation to age 36 months with: iron (12.5 mg) and folicacid (50 microg; n=8337), zinc alone (10 mg), iron, folicacid, and zinc (n=9230), or placebo (n=8683); children aged 1-11 months received half the dose. Our primary outcome measure was all-cause
2006LancetControlled trial quality: predicted high
Homocysteine lowering with folicacid and B vitamins in vascular disease. In observational studies, lower homocysteine levels are associated with lower rates of coronary heart disease and stroke. Folicacid and vitamins B6 and B12 lower homocysteine levels. We assessed whether supplementation reduced the risk of major cardiovascular events in patients with vascular disease.We randomly assigned 5522 patients 55 years of age or older who had vascular disease or diabetes to daily treatment either (...) with the combination of 2.5 mg of folicacid, 50 mg of vitamin B6, and 1 mg of vitamin B12 or with placebo for an average of five years. The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, and stroke.Mean plasma homocysteine levels decreased by 2.4 micromol per liter (0.3 mg per liter) in the active-treatment group and increased by 0.8 micromol per liter (0.1 mg per liter) in the placebo group. Primary outcome events occurred in 519 patients (18.8 percent) assigned
Effect of folicacid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Impact of misclassification of in vitro fertilisation in studies of folicacid and twinning: modelling using population based Swedish vital records. To determine whether failure to adequately adjust for a reported 40% misclassification of use of in vitro fertilisation (IVF) as reported in a Swedish study could have led to a false finding that folicacid increases dizygotic twinning.Modelling with population based data.Swedish vital records for 1995-9.Rates of twinning calculated according (...) to whether women used IVF to become pregnant. Estimated unadjusted and adjusted odds ratios of the association between use of folicacid and twinning by use of IVF.In 1995-9, Swedish women who used IVF had an almost 20 times the chance of having twins than women who did not use IVF (rate ratio 19.7, 95% confidence interval 18.7 to 20.6). In the absence of a true effect of folicacid, the use of a 40% misclassified surrogate variable to adjust for use of IVF would have resulted in a false finding
International retrospective cohort study of neural tube defects in relation to folicacid recommendations: are the recommendations working? To evaluate the effectiveness of policies and recommendations on folicacid aimed at reducing the occurrence of neural tube defects.Retrospective cohort study of births monitored by birth defect registries.13 birth defects registries monitoring rates of neural tube defects from 1988 to 1998 in Norway, Finland, Northern Netherlands, England and Wales (...) applicable).The issuing of recommendations on folicacid was followed by no detectable improvement in the trends of incidence of neural tube defects.Recommendations alone did not seem to influence trends in neural tube defects up to six years after the confirmation of the effectiveness of folicacid in clinical trials. New cases of neural tube defects preventable by folicacid continue to accumulate. A reasonable strategy would be to quickly integrate food fortification with fuller implementation
Folicacid supplements during early pregnancy and likelihood of multiple births: a population-based cohort study. Folicacid supplements are recommended for women of childbearing age to prevent neural tube defects in their offspring. Results of some studies, however, suggest an increase in multiple births associated with use of vitamin supplements that contain folicacid during pregnancy. Our aim was to assess this association.We used data from a population-based cohort study from which we (...) assessed the occurrence of multiple births in women (n=242015) who had participated in a campaign to prevent neural tube defects with folicacid supplements (400 microg per day) in China. Folicacid use was ascertained before pregnancy outcome was known. We studied the relation between multiple births and any use of folicacid pills before or during early pregnancy; additionally, we investigated mechanisms by which folicacid could potentially affect the occurrence of multiple births by examining pill
Folicacid with or without vitamin B12 for cognition and dementia. Folates are vitamins essential to the development of the central nervous system. Insufficient folate activity at the time of conception and early pregnancy can result in congenital neural tube defects. In adult life folate deficiency has been known for decades to produce a characteristic form of anaemia ("megaloblastic"). More recently degrees of folate inadequacy, not severe enough to produce anaemia, have been found (...) and Alzheimer's disease. There is therefore interest in whether dietary supplements of folicacid (an artificial chemical analogue of naturally occurring folates) can improve cognitive function of people at risk of cognitive decline associated with ageing or dementia, whether by affecting homocysteine metabolism or through other mechanisms. There is a risk that if folicacid is given to people who have undiagnosed deficiency of vitamin B12 it may lead to neurological damage. Vitamin B12 deficiency produces
Importance of both folicacid and vitamin B12 in reduction of risk of vascular disease. Fortification of food with folicacid to prevent neural-tube defects in babies also lowers plasma total homocysteine, which is a risk factor for vascular disease. We investigated the effect of folate and vitamin B12 on homocysteine concentrations. 30 men and 23 women received sequential supplementation with increasing doses of folicacid. After supplementation, the usual dependency of homocysteine on folate (...) diminished, and vitamin B12 became the main determinant of plasma homocysteine concentration. This finding suggests that a fortification policy based on folicacid and vitamin B12, rather than folicacid alone, is likely to be much more effective at lowering of homocysteine concentrations, with potential benefits for reduction of risk of vascular disease.
Effect of homocysteine-lowering therapy with folicacid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. Plasma homocysteine level has been recognized as an important cardiovascular risk factor that predicts adverse cardiac events in patients with established coronary atherosclerosis and influences restenosis rate after percutaneous coronary intervention.To evaluate the effect of homocysteine (...) -lowering therapy on clinical outcome after percutaneous coronary intervention.Randomized, double-blind placebo-controlled trial involving 553 patients referred to the University Hospital in Bern, Switzerland, from May 1998 to April 1999 and enrolled after successful angioplasty of at least 1 significant coronary stenosis (> or = 50%).Participants were randomly assigned to receive a combination of folicacid (1 mg/d), vitamin B12 (cyanocobalamin, 400 micro g/d), and vitamin B6 (pyridoxine hydrochloride
Association of neural tube defects and folicacid food fortification in Canada. Many women do not receive folicacid supplements before conception. In response, most of Canada's cereal grain products were being fortified with folicacid by January, 1998, thereby providing an additional 0.1-0.2 mg per day of dietary folate to the Canadian population. We assessed the effect of supplementation on prevalence of open neural tube defects in the province of Ontario. Among 336 963 women who underwent (...) maternal serum screening over 77 months, the prevalence of open neural tube defects declined from 1.13 per 1000 pregnancies before fortification to 0.58 per 1000 pregnancies thereafter (prevalence ratio 0.52, 95% CI 0.40-0.67, p<0.0001). At a population level, folicacid food fortification is associated with a pronounced reduction in open neural tube defects.
Quantifying the effect of folicacid. Folicacid is known to prevent neural-tube defects (NTDs) but the size of the effect for a given dose is unclear. We aimed to quantify such an effect.We used published data from 13 studies of folicacid supplementation on serum folate concentrations and results from a large cohort study of the risk of NTDs according to serum folate, to measure the preventive effect of specified increases in intake of folic acid.Serum folate concentrations increase by 0.94 (...) ng/mL (95% CI 0.77-1.10) for every 0.1 mg/day increase in folicacid intake in women aged 20-35 years, and about double that in people aged 40-65. Every doubling of serum folate concentration roughly halves the risk of an NTD. These two effects can be combined to predict the reduction in risk according to intake of extra folicacid and background serum folate concentration. Such results predict that the preventive effect is greater in women with low serum folate than in those with higher
Folicacid supplements during pregnancy and risk of miscarriage. Although taking supplements that contain 400 microg of folicacid before and during early pregnancy reduces a woman's risk for having a baby with a neural-tube defect (NTD), the effects of such supplements on other pregnancy outcomes remain unclear. We examined whether the use of such supplements affects the occurrence of miscarriage.Participants were women in China who had taken part in a recent folicacid campaign to prevent (...) NTDs and who had registered in this campaign before they became pregnant for the first time. We examined the risk for miscarriage among women who had confirmed pregnancies and who had or had not taken pills containing only 400 microg of folicacid before and during early pregnancy.The overall rate of miscarriage was 9.1% (2155/23806). The rates of miscarriage among women who had and had not taken folicacid pills before and during the first trimester were 9.0% and 9.3%, respectively (risk ratio
Folicacid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. To assess the effects of folicacid and folinic acid in reducing the mucosal and gastrointestinal (GI) and haematologic side effects of low-dose of Methotrexate (MTX) in patients with Rheumatoid Arthritis (RA) and to determine whether or not folate supplementation alters MTX efficacy.We searched the Cochrane Controlled Clinical Trial's Register (CCTR), the Cochrane Musculoskeletal (...) criteria. The total sample included 307 patients, of which 147 were treated with folate supplementation, 80 patients with folinic acid and 67 patients with folicacid. A 79% reduction in mucosal and GI side effects was observed for folicacid [OR = 0.21 (95% CI 0.10 to 0.44)]. For folinic acid, a clinically but non-statistically significant reduction of 43% was found [OR = 0. 57 (95% CI 0.28 to 1.15)]. No major differences were observed between low and high doses of folic or folinic acid. Haematologic
Effect of homocysteine-lowering treatment with folicacid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. A high plasma homocysteine concentration is associated with increased risk of atherothrombotic disease. We investigated the effects of homocysteine-lowering treatment (folicacid plus vitamin B6) on markers of subclinical atherosclerosis among healthy siblings of patients with premature atherothrombotic disease.We did a randomised (...) , placebo-controlled trial among 158 healthy siblings of 167 patients with premature atherothrombotic disease. 80 were assigned placebo and 78 were assigned 5 mg folicacid and 250 mg vitamin B6 daily for 2 years. The primary endpoint was the development or progression of subclinical atherosclerosis as estimated from exercise electrocardiography, the ankle-brachial pressure index, and carotid and femoral ultrasonography.Ten participants in the treatment group, and 14 in the placebo group dropped out
2000LancetControlled trial quality: predicted high